Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial.
about
Prospects for vaccine prevention of meningococcal infectionAn OMV Vaccine Derived from a Capsular Group B Meningococcus with Constitutive FetA Expression: Preclinical Evaluation of Immunogenicity and ToxicitySequence variation in the porB gene from B:P1.4 meningococci causing New Zealand's epidemic.Human opsonins induced during meningococcal disease recognize outer membrane proteins PorA and PorBProtection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis.Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team.Redesignation of a purported P1.15 subtype-specific meningococcal monoclonal antibody as a P1.19-specific reagent.Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccineFunctional activity of anti-Neisserial surface protein A monoclonal antibodies against strains of Neisseria meningitidis serogroup B.Neisseria meningitidis lipopolysaccharide modulates the specific humoral immune response to neisserial porins but has no effect on porin-induced upregulation of costimulatory ligand B7-2.Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccineVariation and molecular evolution of HmbR, the Neisseria meningitidis haemoglobin receptorSterilizing immunity elicited by Neisseria meningitidis carriage shows broader protection than predicted by serum antibody cross-reactivity in CEACAM1-humanized mice.Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvacNovel blocking human IgG directed against the pentapeptide repeat motifs of Neisseria meningitidis Lip/H.8 and Laz lipoproteinsImportance of antibodies to lipopolysaccharide in natural and vaccine-induced serum bactericidal activity against Neisseria meningitidis group B.Serum antibody responses in Ethiopian meningitis patients infected with Neisseria meningitidis serogroup A sequence type 7FetA Antibodies Induced by an Outer Membrane Vesicle Vaccine Derived from a Serogroup B Meningococcal Isolate with Constitutive FetA Expression.Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines.A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial.Hospital-based surveillance of meningococcal meningitis in Salvador, Brazil.Comparison of phenotypically indistinguishable but geographically distinct Neisseria meningitidis Group B isolates in a serum bactericidal antibody assayProspects for eradication of meningococcal diseaseSeroepidemiological study after a long-distance industrial outbreak of legionnaires' disease.Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future.Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design.A common gene pool for the Neisseria FetA antigen.Molecular typing methods for outbreak detection and surveillance of invasive disease caused by Neisseria meningitidis, Haemophilus influenzae and Streptococcus pneumoniae, a reviewSpecificity of subcapsular antibody responses in Ethiopian patients following disease caused by serogroup A meningococci.Antibody specificities and effect of meningococcal carriage in icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccineDevelopment of immunity to serogroup B meningococci during carriage of Neisseria meningitidis in a cohort of university students.Characterization of an antibody depletion assay for analysis of bactericidal antibody specificity.The influence of genomics and proteomics on the development of potential vaccines against meningococcal infectionWorking mechanism of immunoglobulin A1 (IgA1) protease: cleavage of IgA1 antibody to Neisseria meningitidis PorA requires de novo synthesis of IgA1 Protease.Immunoproteomic analysis of the development of natural immunity in subjects colonized by Neisseria meningitidis reveals potential vaccine candidates.
P2860
Q24537338-DF048B05-4E83-4DCA-A876-AC08592A0655Q28607442-4008ABE3-3765-4A96-BA9F-9605487FDE5DQ33825072-5F11F6D7-D0C5-41B5-A507-6C024B99B967Q33867635-81E38CED-78DD-4A41-85A8-5918008771B4Q33946852-903755BE-FFFA-456F-98B2-F38F9B99B954Q33969625-48BE4CD6-4D6C-4640-A666-E29A815EE7C9Q33997835-DB5BB250-DD19-4078-A5C8-CF44F2FBA12DQ34000420-D93A4417-19B2-42CF-80DC-FF39A2B186F2Q34007747-501E15B5-B375-4272-98DD-ABFEF842E1A3Q34008652-50E52DF7-E2DD-4D60-8C5D-C953447DE9D6Q34720380-0ECB7C8D-FF1E-40EE-BDDB-BD7C8D93B283Q34746786-78F5957A-3200-44AC-B25A-792F6262FBE3Q34889968-3362ACA9-71A7-45A4-A069-1EF0CDB1CA6EQ34975624-E08DDA14-8063-4082-B161-354A7CBAE0D6Q35075181-442C5000-3B10-4DE0-B7EF-96895CA34EFFQ35273041-B0D00A40-B2EC-46A7-9283-80FD15CCE3E9Q35783511-98D32395-D3B7-485F-93BE-A237CE1AD7D5Q35806559-782605CA-5F08-46D9-A513-C568380F292EQ35946901-BA40E0C8-7382-4B45-A443-0DB5D7DAAD12Q35949585-30BDAF12-0F3F-497B-BBA3-FA4ABA9D231EQ36094265-46DB7BE7-9497-4225-A250-DEBE78D37F8CQ36313615-C21B4BF1-D40A-4053-999F-307692AEF592Q36440358-574A3E02-3684-4CAD-882C-A6BF42A0AAF3Q37156754-0359DED7-C883-4463-ADB1-AB31E0E010FCQ37514748-E60E8078-7C46-4909-84E0-7E54EC1BF43AQ37523354-BA1E5073-9E5F-4500-B7B6-8234755CE2C3Q37669807-74924BD0-01F5-48F3-AADF-08A8806BE576Q37693513-B9052C07-A145-41CE-8550-62E0687CC925Q38606992-FFBEF672-869E-4FCE-B9B8-7F4C954B4C88Q39777023-2F4BCFAC-D5F4-4EFB-98B9-E97F9E3CF20AQ40204747-B8E3CA72-EE64-4B7B-A9CF-53E60E2F2600Q41774048-AB83C6D6-A1A8-495F-985F-6AC21F79C63FQ41840725-12B9703A-E452-49C8-A3B8-9C744C994134Q41971192-E49BAE76-B75C-4833-A220-7A9D62C15DA2Q42133618-F8AED65A-3205-4513-9D7A-F00EFB95AC26
P2860
Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial.
description
1998 nî lūn-bûn
@nan
1998 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Immune responses against major ...... serogroup B protection trial.
@ast
Immune responses against major ...... serogroup B protection trial.
@en
type
label
Immune responses against major ...... serogroup B protection trial.
@ast
Immune responses against major ...... serogroup B protection trial.
@en
prefLabel
Immune responses against major ...... serogroup B protection trial.
@ast
Immune responses against major ...... serogroup B protection trial.
@en
P2093
P2860
P1476
Immune responses against major ...... serogroup B protection trial.
@en
P2093
P2860
P304
P407
P577
1998-07-01T00:00:00Z